Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

General election 2024 in PP-19 Rawalpindi 13 constituency of Punjab, the stage is set for a vibrant democratic exercise. With many candidates poised to enter the fray, the electoral landscape is abuzz ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics ARCT in the last three months. The table below summarizes their recent ...

General election 2024 in PP-19 Rawalpindi 13 constituency of Punjab, the stage is set for a vibrant democratic exercise. With many candidates poised to enter the fray, the electoral landscape is abuzz ...

November 19, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease ...

H.C. Wainwright maintained a positive stance on Arcturus Therapeutics (NASDAQ:ARCT) shares, reiterating a Buy rating and a price target of $63. Currently trading at $16.97, the stock has significant ...

Arcturus is advancing its vaccine and rare disease pipeline with significant developments. The initiation of a BARDA-funded Phase 1 study for bird flu, along with ongoing studies in cystic ...

After hours: February 7 at 6:22:20 PM EST Loading Chart for ARCT ...

Every year, we are introduced to a new version of iOS (alongside Apple’s other operating systems) at the Worldwide Developers Conference in June. It then marches through an extended beta-testing ...